Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin.

MedStar author(s):
Citation: Atherosclerosis. 235(2):295-8, 2014 Aug.PMID: 24908239Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Observational StudySubject headings: *Diabetes Mellitus, Type 2/dt [Drug Therapy] | *Metformin/tu [Therapeutic Use] | *Percutaneous Coronary Intervention | *Stents/ae [Adverse Effects] | *Thrombosis/ci [Chemically Induced] | Aged | Drug-Eluting Stents/ae [Adverse Effects] | Female | Humans | Male | Middle Aged | Paclitaxel/ad [Administration & Dosage]ISSN:
  • 0021-9150
Name of journal: AtherosclerosisAbstract: CONCLUSION: In NIDDM patients, metformin use or stent type following DES placement did not increase stent thrombosis and MACE rates.Copyright � 2014 Elsevier Ireland Ltd. All rights reserved.METHODS: We assessed the impact of metformin and stent type on stent thrombosis, MACE, and death in NIDDM patients following DES placement. Of the 1201 patients included, 74.8% received LES, 25.2% received paclitaxel-eluting stents (PES), and 55% were taking metformin.OBJECTIVE: Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis. Therefore, we assessed the impact of metformin on stent thrombosis and major adverse cardiovascular events (MACE) in non-insulin-dependent diabetes mellitus (NIDDM) patients who receive drug-eluting stents (DES).RESULTS: There was no difference in stent thrombosis, regardless of stent type or metformin use. While Kaplan-Meier curves demonstrated reduced MACE (p = 0.007) and death (p = 0.006) with metformin use, multivariate analysis demonstrated that stent type and metformin use were not associated with outcome.All authors: Chen F, Lipinski MJ, Pendyala LK, Torguson R, Waksman RDigital Object Identifier: Date added to catalog: 2015-04-29
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 24908239

CONCLUSION: In NIDDM patients, metformin use or stent type following DES placement did not increase stent thrombosis and MACE rates.Copyright � 2014 Elsevier Ireland Ltd. All rights reserved.

METHODS: We assessed the impact of metformin and stent type on stent thrombosis, MACE, and death in NIDDM patients following DES placement. Of the 1201 patients included, 74.8% received LES, 25.2% received paclitaxel-eluting stents (PES), and 55% were taking metformin.

OBJECTIVE: Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis. Therefore, we assessed the impact of metformin on stent thrombosis and major adverse cardiovascular events (MACE) in non-insulin-dependent diabetes mellitus (NIDDM) patients who receive drug-eluting stents (DES).

RESULTS: There was no difference in stent thrombosis, regardless of stent type or metformin use. While Kaplan-Meier curves demonstrated reduced MACE (p = 0.007) and death (p = 0.006) with metformin use, multivariate analysis demonstrated that stent type and metformin use were not associated with outcome.

English

Powered by Koha